CircMED13L_012 promotes lung adenocarcinoma progression by upregulation of MAPK8 mediated by miR-433-3p

Wenshu Chen1†, Guanying Zheng2†, Jianyuan Huang1, Lihuan Zhu1, Wujin Li1, Tianxing Guo1, Yangyun Huang1 and Xiaojie Pan1*

Abstract

Background: Metastasis and disease refractoriness remain as major challenges for non-small cell lung cancer (NSCLC) treatment and understanding the underlying molecular mechanisms is of scientific and clinical value. Therefore, in this study, we aimed to explore the effects of circMED13L_012 on the proliferation, migration, invasion and drug-resistance of NSCLC tumor cells.

Methods: In this study, we utilized clinical samples and NSCLC cell lines to explore the association between circMED13L_012 expressions and tumor cell metastasis and chemo resistance. CCK8 and transwell assay were conducted to explore the impact of circMED13L_012 on NSCLC tumor proliferation and migrative capabilities. Dual-luciferase reporter gene assay was conducted to validate the circMED13L_012 interaction network.

Results: Our results demonstrated that circMED13L_012 exhibited significantly elevated average level in our clinical samples of NSCLC, compared with normal tissues. circMED13L_012 level was positively correlated with disease stage and metastatic status. Increased circMED13L_012 expression was associated with the enhanced migration, proliferation and chemo resistance of NSCLC cell lines. Further experiments indicated that circMED13L_012 promoted malignant behavior of NSCLC tumor cells by targeting MAPK8 through modulation miR-433-3p expression.

Conclusions: Our study for the first time demonstrated that circMED13L_012–miR-433-3p–MAPK8 axis played important role for NSCLC pathogenesis, which could be potential therapeutic target for the development of future NSCLC treatment.

Keywords: NSCLC, circMED13L_012, MAPK8
of a range of microRNAs [4, 5]. Current researches demonstrated that circRNAs were involved in the pathogenesis of multiple malignant diseases including colorectal cancer [6], hepatocellular carcinoma [7], breast cancer [8] and gastric cancer [9]. And another research demonstrated that tumor epithelial to mesenchymal transition (EMT) process was also closely associated with circRNAs biogenesis [10], which indicating potential roles of circRNAs in tumor metastasis.

However, up till now, the exact role of circMED13_012 in lung cancer pathogenesis and disease progression remains undiscovered. Therefore, in this study, we aimed to evaluate the molecular impact of circMED13_012 on lung cancer cells and further explore the gene regulatory network of circMED13_012 for NSCLC.

Materials and methods

Patient recruitment and sample collection
A total of 180 patients diagnosed with NSCLC in our cancer center receiving surgical treatment during Jan 2019 to Dec 2019 were included in our study. 120 patients’ tumor biopsy samples and adjacent normal tissues were acquired. Tissues were stored immediately after surgical resection using liquid nitrogen. Informed consent was obtained for all patients enrolled in this study. And our study was approved by Ethical Committee of Fujian Provincial Hospital.

Cell line culturing
NSCLC cell line NCI-H1299, H1975, SPC-A-1, A549 and normal human bronchial epithelial cell line HNBE were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were cultured using RPMI-1640 medium with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) was added. Cells for each group were inoculated into 96-well plates with a density of 1 × 10^3 cells/well. Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Kumamoto, Japan) solution (10 µL) was added to each well after 1, 2, 3, 4 and 5 days, respectively. Afterwards cells were incubated at 37 °C for 1 h. Chemiluminescence was used to expose the protein bands on the membrane.

Cell transfection
NCI-H1299 and A549 cells were placed into 8-well plates with density of 1 × 10^6 cells per well. Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used for transfection of vectors including circMED13L_012 overexpression plasmid, miR-433-3p mimics and inhibitor, sh-circMED13L_012, MAPK8 siRNAs according to the instructions of manufacturer.

Real time qRT-PCR quantification
TRizol agent (Invitrogen, Thermo Fisher Scientific, Inc) was used for RNA extraction according to the standardized protocol. cDNA was collected through reverse transcription for subsequent qRT-PCR experiments. qRT-PCR reaction condition was set as 94°C for 30s, 55°C for 30s, 72°C for 90s, with total cycles of 45. Primers used in this study include: MED13L primers forward 5′-TGCTGTCAGAGCAAGCGAG – 3′; reverse 5′-GAT CGGTCTGAAGAGCCGAGC-3; U6 forward, 5′-CTC GTTTCGCGACGACAT-3; reverse, 5′-AACGGTCTGA CGAATTTCGCT-3; miR-433-3p forward, 5′-GGAGAA GTACGGTACGCTG-3; reverse, 5′-CAGTGGCTGT TCGTGGAGT-3; Actin forward, 5′-GTCACCACGG AAATGCTTCTA-3; reverse, 5′-TGCTGTACACCTT CACCGTTC-3.

Western blot
RIPA agent (Beyotime, Shanghai, China) was used to extract protein from the clinical samples and proteins were quantified by BCA assay. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis was used to separate proteins and then proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA). The membranes were incubated at 4 °C overnight with primary antibody (Cell Signaling Technology, Danvers, MA, USA), after subsequently rinsing with the tris-buffered salin and Tween buffer solution (TBST; Sigma-Aldrich, St. Louis, MO, USA), membranes were then incubated with the secondary antibody at room temperature for 1 h. Chemiluminescence was used to expose the protein bands on the membrane.

Cell proliferation CCK8 assay
Prior to experiments, cells from each treatment/control group were inoculated into 96-well plates with a density of 1 × 10^3 cells/well. Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Kumamoto, Japan) solution (10 µL) was added to each well after 1, 2, 3, 4 and 5 days, respectively. Afterwards cells were incubated at 37 °C for 1 h. The absorbance was recorded of each well at 450 nm by a microplate reader.

Cell survivability and migration assay
2 × 10^6 Cells for each group were treated for 4 h with a series of dosage of chemoagents including docetaxel, doxorubicin, gefitinib. Then cells were washed with cold PBS before incubation with 75% ethanol at −20 °C overnight. Cells were stained with 10 µL of propidium iodide (PI) and Annexin V-FITC (Thermo Fisher Scientific) for 20 min at room temperature, and flow cytometry (FACScan™, BD Biosciences, Franklin Lakes, NJ, USA) analysis was performed for evaluation of cellular apoptosis. 6 × 10^4 transfected cells were put into the upper chamber (8-µm) (Corning, Lowell, MA, USA). As for the bottom chamber, the medium with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) was added. Cells for each
experimental group were respectively incubated under 37 °C, 5% CO2 condition for 48 h. Penetrating cells were fixed in 70% ethanol for 40 min and stained with 0.1% crystal violet for 15 min. Five randomly selected fields for each sample was selected for the number calculation of penetrating cells.

RNA-immunoprecipitation
Nuclear proteins of cells were extracted according to the manufacturer's instructions. 10% of the total nuclear protein was used as input control. Anti-IgG and anti-Ago2 antibodies were then used to incubate with the remaining protein at 4 °C for 2 h, and protein was subsequently incubated with protein A/G plus-agarose at 4°C overnight. The proteins were then centrifuged at 4°C, 2000 r/min for 1 min. The precipitate was re-suspended in NETN100. 10% of precipitate, and input control and IgG sample were used for protein level quantification. The remaining samples were used for RNA isolation, purification and identification.

Dual-luciferase reporter gene assay
Prior to experimental procedures, cells were digested using trypsin. Then cells were inoculated into 24-well plates before transfection. Transfection reagents were prepared as described below: Tube A: circMED13L_012-WT plasmid and circMED13L_012-MUT plasmid or MAPK8-WT/MUT plasmid were mixed with culture medium; Tube B: miR-433-3p-WT plasmid and miR-NC plasmid were mixed with culture medium; Tube C: transfection reagent was mixed with culture medium. Tube C mixture was separately added into Tube A and B. Mixtures in Tube A and B were added in each well and incubated for 48 h. Transfection efficiency was observed by a fluorescence microscope (Leica, Wetzlar, Germany).

Statistical analysis
Statistical Product and Service Solutions (SPSS) 22.0 (Chicago, IL, USA) was applied for all statistical analysis. GraphPad Prism software (Version X; La Jolla, CA, USA) was introduced for figure processing. Experimental data were expressed as mean ± standard deviation (SD). Results among more than 2 groups was analyzed using one-way analysis of variance (ANOVA). Student's t test was applied to analyze data between 2 groups. p < 0.05 was considered statistically significant.

Results
Characterization of circMED13L_012 and its expression pattern in NSCLC samples
As shown in Fig. 1a, CircMED13L_012 was located at Chromosome 12: 116,534,473–116,675,510, with a length of 407 bp. RNase treatment experiment indicated the relatively high structural stability of circMED13L_012, compared with MED13L mRNA (Fig. 1b). Further experiments using actinomycin D, which is a transcription inhibitor, indicated that circMED13L_012 circular transcripts were more stable compared with linear transcripts of MED13L mRNA (Fig. 1c). In addition, by qRT-PCR method, we further compared the expression level of MED13L mRNA and circMED13L_012 in cellular cytoplasmic and nuclear region. As a result, MED13L mRNA and circMED13L_012 were shown to be significantly enriched in cytoplasm (Fig. 1d).

Then, in order to understand the association between circMED13L_012 and disease status in NSCLC patients, we performed qRT-PCR study to detect circMED13L_012 expression value in NSCLC and matched normal tissue samples. Our study demonstrated that circMED13L_012 expression levels were significantly higher, in comparison with normal tissues (Fig. 1e). While there is no significantly different level of MED13L mRNA expression level between NSCLC tumor samples and matched normal tissues (Fig. 1f). Furthermore, circMED13L_012 levels among NSCLC tumor samples of different stages were compared and results indicated that advanced-stage NSCLC patients (stage III-IV) showed significantly higher level of circMED13L_012 expression level in comparison with early stage tumor samples (stage I/II) (Fig. 1g). As for samples of patients with advanced stage of lymphoid node metastatic diseases (N2), they also exhibited significantly higher level of circMED13L_012 comparing with patients in N1 or N0 status. Meanwhile, N1 patients also showed significantly higher that no status patients. (Fig. 1h). Consistently, patients with distal organ metastatic disease (M1) also demonstrated increased circMED13L_012 level in their tumor cells, comparing with patients without distal organ metastasis (M0) (Fig. 1i). Next, qRT-PCR detection of circMED13L_012 expression levels also indicated that circMED13L_012 levels in several NSCLC cell lines (NCI-H1299,H1975, SPC-A-1, A549) were significantly higher compared to normal human bronchial epithelial cell line HNBE (Fig. 1j).

Effects of circMED13L_012 on the malignant behavior of NSCLC cell lines
To further investigate the role of circMED13L_012 played in NSCLC pathogenesis, in this study we utilized three different circMED13L_012-specific shRNAs and circMED13L_012 over-expression vector to modulate circMED13L_012 expression. As shown in Fig. 2a and b, all three shRNAs and circMED13L_012 over-expression vector exhibited significant suppressive and promotive effects on circMED13L_012 level, while they had no influences on the mRNA expression level.
of MED13L. Next, we evaluated the effects of circM-ED13L_012 expression modulation on tumor cell survivability under treatment of several chemotherapeutic agent including docetaxel, doxorubicin and gefitinib. By transfection of sh-circMED13L_012 and circMED13L_012 overexpression vector into A549 cells, our study results indicated that cells transfected with sh-circMED13L_012 exhibited significantly suppressed chemo-resistance. In the meantime, cells transfected with circMED13L_012 over expression vector demonstrated significantly promoted survivability compared with normal control (Fig. 2c–e).

Fig. 1 Characterization of circMED13L_012 and its expression pattern in NSCLC samples. a Schematic illustration of chromosomal location of circMED13L_012. b qRT-PCR analysis of circMED13L_012 and MED13L mRNA level in A549 cells which were treated by RNase or negative control respectively. c qRT-PCR analysis of circMED13L_012 and MED13L mRNA level in A549 cells which were treated by actinomycin-D or negative control respectively for different period of time (0 h, 6 h, 12 h, 18 h, 24 h). d relative expression level detection of circMED13L_012, MED13L, GAPDH and U6 in cytoplasmic or nuclear region of A549 cells. e, f Comparison of circMED13L_012 and MED13L expression level between NSCLC and matched normal lung tissues. g Comparison of circMED13L_012 expression level between early stage (T1, T2) and advanced stage (T3, T4) NSCLC tumors samples. h Comparison of circMED13L_012 expression level in NSCLC tumor samples with or without lymph node metastasis. i Comparison of circMED13L_012 expression level in NSCLC tumor samples with or without distal organ metastatic disease. j Comparison of circMED13L_012 expression level among different NSCLC cell lines (NCI-H1975, NCI-H1299, A549, SPC-A-1) and human normal bronchial epithelial cell line HNBE.
Then, we evaluated the influences of circMED13L_012 modulation on the proliferative abilities of NSCLC cell lines. As shown in Fig. 3a and b, sh-circMED13L_012 treated A549 cells exhibited significantly decreased cell proliferation compared with control group, while circMED13L_012 overexpression in NCI-H1299 significantly promoted cellular proliferation. In addition, after treatment with sh-circMED13L_012, the migration and invasion ability of A549 cells were remarkably suppressed (Fig. 3c). However, circMED13L_012 overexpression significantly promoted the cell migration and invasion of NCI-H1299 cells (Fig. 3d). The protein levels of Ki67, N-Cadherin, and vimentin were remarkably suppressed by sh-circMED13L_012, but the expression of E-Cadherin was significantly increased (Fig. 3e, f). However, circMED13L_012 overexpression exerted opposite influence on the levels of Ki67, E-Cadherin, N-Cadherin, and vimentin (Fig. 3g). circMED13L_012 overexpression significantly increased the levels of Ki67, E-Cadherin, and vimentin, but inhibited N-Cadherin. The results demonstrated that circMED13L_012 over expression was significantly related with enhanced cellular expression of Ki67, vimentin and N-cadherin and suppressed expression of E-Cadherin.

**circMED13L_012 modulates miR-433-3p expression**

As it is well known that circRNAs regulate miRNAs expression by acting as molecular sponges through interaction with RNA-induced silencing complex (RISC). In order to further explore the detailed molecular mechanism of circMED13L_012, we performed bioinformatic prediction of circMED13L_012 interacting miRNAs. As shown in Fig. 4a, by cross-checking prediction results of two circRNA-miRNA interaction online platforms (Circinteractome, https://circinteractome.nia.nih.gov and Starbase, http://starbase.sysu.edu.cn), we identified a total of 3 miRNAs (miR-433-3p, miR-503-3p and miR-330-3p) that potentially interacted with circMED13L_012. Further validation
analysis on NSCLC clinical samples demonstrated that only miR-433-3p expression level was negatively correlated with circMED13L_012 expression which reached statistical significance ($r = -0.398$, $P = 0.000$) (Fig. 4b and d). By prediction of binding site of circMED13L_012 with miR-433-3p (Fig. 4e), we performed dual-luciferase reporter gene assay in vitro using vectors carrying wildtype and mutated circMED13L_012 and miR-433-3p or control. Our results indicated that luciferase activity of miR-433-3p was significantly suppressed for A549 and NCI-H1299 tumor cells transfected by wildtype circMED13L_012 vector, in comparison with cell group transfected with mutated circMED13L_012 vector (Fig. 4f). While cell group with wild type-circMED13L_012 vector treated with sh-circMED13L_012 exhibited significantly increased miR-433-3p level, in comparison with mutated circMED13L_012 vector group (Fig. 4g). RNA immunoprecipitation (RIP) experiments using Ago2 antibody demonstrated that both circMED13L_012 and miR-433-3p were significantly enriched with Ago2 (Argonaute) antibodies compared with control IgG ($P < 0.001$) (Fig. 4h and i), indicating their functions were closely associated with RISC. Moreover,
circMED13L_012 expression modulation via sh-circMED13L_012 and circMED13L_012 overexpression vector presented significant influences on miR-433-3p treatment ($P < 0.001$) (Fig. 4j).

circMED13L_012 modulates miR-433-3p and exerts its biological effects by interacting with MAPK8 gene

In order to explore the detailed mechanism of circMED13L_012 - miR-433-3p regulatory axis, we performed...
targets gene prediction of miR-433-3p via online miRNA-
gene interacting platforms including DIANA, TargetScan
and miRDB, and a total of five genes (MAPK8, CCDC138,
B4GALT3, CEP135 and TOP1) as potential target of
miR-433-3p were identified for all three databases
(Fig. 5a). qRT-PCR validation on NSCLC clinical samples
indicated that only MAPK8 gene was shown to be nega-
tively correlated with miR-433-3p expression level, which
was statistically significant (Fig. 5b and f) (r = -0.358,
P = 0.000). To confirm the interaction of miR-433-3p and
MAPK8 gene, two different miR-433-3p binding sites of
MAPK8 3’UTR region were identified and vectors car-
rying WT-MAPK8-3’UTR and MUT-MAPK8-3’UTR
regions were generated (Fig. 5g). miR-433-3p mim-
ics / specific inhibitors were also constructed and their
modulation effects on miR-433-3p expression were also
evaluated (Fig. 5h). Dual-luciferase reporter gene assay
was also performed on A549 and NCI-H1299 cell lines
transfected with miR-433-3 mimics / specific inhibitors,
in combination of vectors carrying WT-MAPK8-3’UTR
and MUT-MAPK8-3’UTR region, respectively. Experi-
ments results demonstrated that miR-433-3 specific
inhibitors significantly increased luciferase activity in
cells transfected with WT-MAPK8-3’UTR vector com-
pared with cells transfected with MUT-MAPK8-3’UTR
(Fig. 5i). Additionally, treatment with miR-433-3 mimics
significantly suppressed luciferase activity in cells with
WT-MAPK8-3’UTR vectors (Fig. 5j). While no signifi-
cant differences in luciferase activities were shown in cell
group with MUT-MAPK8-3’UTR vector. Consistently,
western-blot and qRT-PCR study results also confirmed
the modulatory activities of miR-433-3 mimics / specific
inhibitors on MAPK8 protein/mRNA expression (Fig. 5k
and l).

Finally, to validate the biological effects of
circMED13L_012-miR-433-3p–MAPK8 axis in NSCLC
cells identified in this study, we designed MAPK8-spe-
cific siRNAs and validated their suppressive effects on
MAPK8 mRNA/protein expression (Fig. 6a). Cell pro-
liferation assay and performed on NCI-H1299 cells
transfected by MAPK8 siRNA with or without circ-
MED13L_012 overexpression vectors indicated that
MAPK8 siRNAs abrogated circMED13L_012 promo-
tive effects on cellular proliferation (Fig. 6b). Cellu-
lar survival experiments were also performed on A549
and NCI-H1299 cells treated with different concentra-
tions of docetaxel, doxorubicin and gefitinib (Fig. 6c–e).
Results indicated that MAPK8 siRNAs also abrogated
the increased cellular survivability caused by circM-
ED13L_012 overexpression. Western Blot and qRT-PCR
experiments also confirmed that by transfection of circ-
MED13L_012 overexpression vector, MAPK8 protein
and mRNA level was significantly elevated, while such
effects were abrogated by co-transfection of miR-433-3p
mimics (Fig. 6f and g). On the other hand, sh-circM-
ED13L_012 generated suppressive effects on MAPK8
mRNA and protein expression, and its suppressive effects
were further elevated by co-transfection of miR-433-3p
mimics (Fig. 6h and i).

Discussion
As it is well acknowledged that NSCLC is a geneti-
cally heterogeneous disease, multiple signaling pathways
involving cell proliferation and survival play important
parts in NSCLC pathogenesis. Among them, MAPK
pathway has been demonstrated as important compo-
ent in NSCLC pathogenesis [11]. Genetic mutations
of several key kinases along MAPK pathways including
RAS, RAF, MEK and ERK have been indicated to account
for the increased tumor proliferative abilities as well
as survival and chemo-resistance. For example, KRAS
mutation was found in 30% of lung adenocarcinoma
patients [12], while BRAF mutation was less frequent.
MEK1 and MEK2 were known as downstream compo-
nents of KRAS/RAF signaling pathway, and current stud-
ies have shown they were potential therapeutic targets
for NSCLC and specific inhibitor, Trametinib has been
developed and exhibited promising effects in clinical tri-
als [13–15].

On the other hand, MAPK 8/9/10 (also known as JNK
1/2/3) are also components in MAPK pathway [16] but
their functions in NSCLC were not fully understand. Re-
cent study indicated that MAPK8/9/10 activation via
Rabl3 depletion was associated with enhanced autophagy
for lung cancer cells [17], this phenomenon was consist-
ent with previous findings that MAPK signaling pathway
activation was associated with autophagy enhancement
in ovarian and gastric cancer cells [18, 19]. Therefore,
increased tumor chemo-resistance of NSCLC caused by
MAPK8 expression elevation could possibly be explained
by enhanced tumor cellular autophagy, once more mech-
anismic studies were performed to further confirm such
putative link.

In this study, we demonstrated for the first time
that circMED13L_012 regulated MAPK8 expres-
sion level by reducing miR-433-3p level in NSCLC
patients. Currently, little is known about the molecu-
lar function and its pathological significance of circM-
ED13L_012 in NSCLC. However, previous studies did
find that MED13L gene played interesting part in the
radio-sensitivity of NSCLC tumor cells, as radiation
triggers silencing of MED13L and MED13L suppres-
sion decreased their physical interactions and reduced
recruitment of acetyltransferase P300 to chromatin
via Mediator complex, and they in turn suppressed the
activities of multiple oncogenes [20]. In this study,
Fig. 5  circMED13L_012 modulates miR-433-3p through affecting MAPK8. a miR-433-3p target gene prediction based on three microRNA-gene interaction databases including DIANA, miRDB and TargetScan. b–f qRT-PCR study exploring the association of miR-433-3p expression level and MAPK8 (B), CCDC138 (C), B4GALT3 (D), CEP135 (E), TOP1 (F) mRNA expression level in NSCLC clinical samples. g Prediction of miR-433-3p binding site with wildtype MAPK8 3’UTR region and design of vector including mutated MAPK8 3’UTR region. h qRT-PCT validation of the impact of miR-433-3p specific mimics and inhibitor on miR-433-3p expression. i, j Dual luciferase reporter gene assay to evaluate modulative effects of miR-433-3p specific inhibitor (I) and mimics (J) on MAPK8 expression. k Western blot analysis on the modulative effects of miR-433-3p specific inhibitor and mimics on the MAPK8 protein expression level.
although we found no significant association of circMED13L_012 expression with MED13L mRNA level, the potential interactions of circMED13L_012 with Mediator complex in NSCLC pathogenesis required further investigation.

Moreover, our study presented consistent results of the suppressive effects of miR-433-3p on tumor cell proliferation. Previous researches have demonstrated that miR-433-3p attenuated glioma cell growth and invasion/migration by targeting CREB [21]. Besides, another
study indicated that for esophageal squamous cell carcinoma, miR-433-3p overexpression also exhibited inhibitory effects on tumor cells proliferation, invasion, and migration. And study also demonstrated that growth factor receptor-bound protein 2 (GRB2) is the target of miR-433-3p that mediated the tumor inhibitory function of miR-433-3p [22]. Additionally, miR-433-3p were also shown to possess tumor inhibitory effects in osteosarcoma [23], breast cancer [24], bladder cancer [25], renal carcinoma [26]. As for NSCLC, previous studies also showed that miR-433-3p targeted WT1 associated protein (WTAP) to reduced tumor cell proliferation and migration. Therefore, based on previous findings and our study results, miR-433-3p could be valuable therapeutic target in future NSCLC treatment, once further detailed studies could be performed to fully unveil its role in NSCLC pathogenesis and disease progression. Therefore, therapeutic strategies inhibiting circMED13L_012 or MAPK8 and promoting miR-433-3p could be used in the future for NSCLC patient treatment.

There are some limitations in this study. Firstly, it is better to perform xenograft tumors experiments in vivo to confirm the role of circMED13L_012/miR-433-3p/MAPK8 in regulating tumors. Secondly, influence of circMED13L_012/miR-433-3p/MAPK8 on the apoptosis and cell cycle of tumor cells was missing in this study.

Conclusions
Our study demonstrated for the first time that circMED13L_012 played unique part in promotion NSCLC tumor cell proliferation, invasion and chemoresistance. circMED13L_012 could be valuable predictive biomarker for NSCLC prognosis and metastasis evaluation. And circMED13L_012-miR-433-3p-MAPK8 axis presented in our study could be novel therapeutic target for future NSCLC treatment.

Abbreviations
circRNAs: Circular RNAs; EMT: Epithelial to mesenchymal transition; PVDF: Polyvinylidene difluoride; PI: Propidium iodide; RISC: RNA-induced silencing complex; RIP: RNA immunoprecipitation; WTAP: WT1 associated protein.

Acknowledgements
Not applicable.

Authors’ contributions
WC and GZ conceived and designed the project; WC and GZ collected the data; JH and LZ performed this study; WL, TG and YH performed the interpretation of data and statistical analysis; WC and GZ wrote the manuscript. XP revised the paper. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets used and analyzed in the current study are available from the corresponding author in response to reasonable requests.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Cancer J Clin. 2020;70(1):7–30.
2. Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016;35(1):75–91.
3. Liu WJ, Du Y, Wen R, Yang M, Xu J. Drug resistance to targeted therapeutic strategies in nonsmall cell lung cancer. Pharmacol Ther. 2020;206:107438.
4. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–8.
5. Guo JU, Agarwal V, Guo H, Bartel DP. Expanded identification and characterization of mammalian circular RNAs. Genome biology. 2014;15(7):409.
6. Bachmayr-Heyda A, Reiner AT, Auer K, Sukhbaatar N, Aust S, Bachleitner-Hofmann T, Mesteri I, Grunt TW, Zeilinger R, Pils D. Correlation of circular RNA abundance with proliferation–exemplified with colorectal and ovarian cancer, idiopathic lupus fibrosis, and normal human tissues. Scientific reports. 2015;5:8057.
7. Qin M, Liu G, Huo X, Tao X, Sun X, Ge Z, Yang J, Fan J, Liu L, Qin W. Hsa_circ_0001649: A circular RNA and potential novel biomarker for hepatocellular carcinoma. Cancer Biomark A. 2016;16(1):161–9.
8. Nair AA, Niu N, Tang X, Thompson KJ, Wang L, Kocher JP, Subramanian S, Kalani KR. Circular RNAs and their associations with breast cancer subtypes. Oncotarget. 2016;7(49):80967–79.
9. Li P, Chen S, Chen H, Mo X, Li T, Shao Y, Xiao B, Guo J. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin Chim Acta. 2015;444:132–6.
10. Zhao ZJ, Shen J. Circular RNA participates in the carcinogenesis and the malignant behavior of cancer. RNA Biol. 2017;14(5):514–21.
11. Jeanson A, Boyer A, Grellier L, Tomasin P, Barlesi F. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in nonsmall cell lung cancer. Expert Rev Anticancer Ther. 2019;19(1):11–7.
12. Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mossier J, Lena H, Ouaifik L, Besse B, Rouquette I, Westeel V, et al. Routine molecular profiling of patients with advanced nonsmall-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415–26.
13. Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, DAmeolo AM Jr, Zhang P, Mooijerje B, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307–16.
14. Blumenschein GR Jr, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Uldum K, Ahn MJ, Hanna NH, et al. A randomized phase II study of the mTOR inhibitor temsirolimus (GSK1120212) compared with docetaxel in KRAS-mutant advanced nonsmall-cell lung cancer (NSCLC). Ann Oncol. 2015;26(5):894–901.
15. Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, et al. A phase 1/1b study evaluating trametinib plus docetaxel or pemetrexed in patients with advanced non-small cell lung cancer. J Thor Oncol. 2017;12(3):556–66.

16. Sun Y, Liu WZ, Liu T, Feng X, Yang N, Zhou HF. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res. 2015;35(6):600–4.

17. Zhang W, Sun J, Luo J. High Expression of Rab-like 3 (Rabl3) is Associated with Poor Survival of Patients with Non-Small Cell Lung Cancer via Repression of MAPK8/9/10-Mediated Autophagy. Med Sci Monit. 2016;22:1582–8.

18. Wu WK, Cho CH, Lee CW, Wu YC, Yu L, Li ZJ, Wong CC, Li HT, Zhang L, Ren SX, et al. Macropathology and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells. Autophagy. 2010;6(2):228–38.

19. Liu Y, Tao X, Jia L, Cheng KW, Lu Y, Yu Y, Feng Y. Knockdown of RAB25 promotes autophagy and inhibits cell growth in ovarian cancer cells. Mol Med Rep. 2012;6(5):1006–12.

20. Zhang N, Song Y, Xu Y, Liu J, Shen Y, Zhou L, Yu J, Yang M. MED13L integrates Mediator-regulated epigenetic control into lung cancer radiosensitivity. Theranostics. 2020;10(20):9378–94.

21. Sun S, Wang X, Xu X, Di H, Du J, Xu B, Wang Q, Wang J. MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma. Oncotarget. 2017;8(3):5057–68.

22. Shi Q, Wang Y, Mu Y, Wang X, Fan Q. MiR-433-3p Inhibits Proliferation and Invasion of Esophageal Squamous Cell Carcinoma by Targeting GRB2. Cell Physiol Biochem. 2018;46(5):2187–96.

23. Hou KK, Mao JS. Long noncoding RNA SNHG14 promotes osteosarcoma progression via miR-433-3p/FBXO22 axis. Biochem Biophys Res Commun. 2020;523(3):766–72.

24. Liu SQ, Zhou ZY, Dong X, Guo L, Zhang KJ. LncRNA GNAS-AS1 facilitates ER + breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p/GATA3 axis. Bioscience Rep. 2020. https://doi.org/10.1042/BSR20200626.

25. Wang F, Fan M, Cai Y, Zhou X, Tai S, Yu Y, Wu H, Zhang Y, Liu J, Huang S, et al. Circular RNA circRIMS1 acts as a sponge of miR-433-3p to promote bladder cancer progression by regulating CCAR1 expression. Mol Ther Nucl Acids. 2020;22:815–31.

26. Cai X, Zhang X, Mo L, Zhu J, Yu H. LncRNA PCGEM1 promotes renal carcinoma progression by targeting miR-433-3p to regulate FGF2 expression. Cancer Biomark A. 2020;27(4):493–504.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.